-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PLRX
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
-
Pliant Therapeutics (PLRX) PT Lowered to $1.50 at Citi
-
Citi Downgrades Pliant Therapeutics (PLRX) to Neutral
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Citi Reiterates Buy Rating on Pliant Therapeutics (PLRX)
-
Pliant Therapeutics (PLRX) PT Lowered to $44 at Citi
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Citi Starts Pliant Therapeutics (PLRX) at Buy
-
Pliant Therapeutics to Participate in Upcoming Virtual Investor Events
-
Pliant Therapeutics to Participate in Upcoming Virtual Investor Events
-
FibroGen (FGEN), Pliant Therapeutics (PLRX) to Benefit from Galapagos (GLPG)/Gilead (GILD) Discontinued ISABELA Phase 3 Trials in IPF - Citi
-
Pliant Therapeutics To Participate In Upcoming Virtual Investor Conferences
-
Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares
-
Pliant Therapeutics (PLRX) IPO Opens 57% Higher
-
Pliant Therapeutics, Inc. (PLRX) Prices 9M Share IPO at $16/Sh
-
Pliant Therapeutics Announces Pricing of Initial Public Offering

